Gritstone Bio Files for Chapter 11 Bankruptcy

Dow Jones2024-10-10

By Colin Kellaher

Gritstone bio has filed for chapter 11 bankruptcy, as the clinical-stage biotechnology company continues to explore strategic alternatives.

Gritstone on Thursday said it plans to use the bankruptcy court-administered restructuring process to preserve value and bolster its capital position as it continues a Phase 2 study of its immunotherapy candidate in colorectal cancer.

The Emeryville, Calif., company, which last month reported encouraging interim data from the study, said the chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware affords it the additional time needed for the data to mature.

Gritstone last month also said it had hired Raymond James as its financial adviser to assist in reviewing potential value-maximizing strategies.

The company on Thursday said it is in talks with an undisclosed party to act as a lead bidder or restructuring plan sponsor, adding that it plans to present an agreement for a value-maximizing transaction to the bankruptcy court as early as next week.

Shares of Gritstone, which closed Wednesday at 19.8 cents, were recently down 32% to 13.5 cents in premarket trading. Shareholders are generally wiped out in bankruptcy cases.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 10, 2024 06:21 ET (10:21 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474718823?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-10 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474718823","market":"sg","top_or_hot":-1,"title":"Gritstone Bio Files for Chapter 11 Bankruptcy","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Gritstone bio has filed for chapter 11 bankruptcy, as the clinical-stage biotechnology company continues to explore strategic alternatives. \n</p>\n<p>\n  Gritstone on Thursday said it plans to use the bankruptcy court-administered restructuring process to preserve value and bolster its capital position as it continues a Phase 2 study of its immunotherapy candidate in colorectal cancer. \n</p>\n<p>\n  The Emeryville, Calif., company, which last month reported encouraging interim data from the study, said the chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware affords it the additional time needed for the data to mature. \n</p>\n<p>\n  Gritstone last month also said it had hired Raymond James as its financial adviser to assist in reviewing potential value-maximizing strategies. \n</p>\n<p>\n  The company on Thursday said it is in talks with an undisclosed party to act as a lead bidder or restructuring plan sponsor, adding that it plans to present an agreement for a value-maximizing transaction to the bankruptcy court as early as next week. \n</p>\n<p>\n  Shares of Gritstone, which closed Wednesday at 19.8 cents, were recently down 32% to 13.5 cents in premarket trading. Shareholders are generally wiped out in bankruptcy cases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 10, 2024 06:21 ET (10:21 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gritstone Bio Files for Chapter 11 Bankruptcy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGritstone Bio Files for Chapter 11 Bankruptcy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-10 18:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Gritstone bio has filed for chapter 11 bankruptcy, as the clinical-stage biotechnology company continues to explore strategic alternatives. \n</p>\n<p>\n  Gritstone on Thursday said it plans to use the bankruptcy court-administered restructuring process to preserve value and bolster its capital position as it continues a Phase 2 study of its immunotherapy candidate in colorectal cancer. \n</p>\n<p>\n  The Emeryville, Calif., company, which last month reported encouraging interim data from the study, said the chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware affords it the additional time needed for the data to mature. \n</p>\n<p>\n  Gritstone last month also said it had hired Raymond James as its financial adviser to assist in reviewing potential value-maximizing strategies. \n</p>\n<p>\n  The company on Thursday said it is in talks with an undisclosed party to act as a lead bidder or restructuring plan sponsor, adding that it plans to present an agreement for a value-maximizing transaction to the bankruptcy court as early as next week. \n</p>\n<p>\n  Shares of Gritstone, which closed Wednesday at 19.8 cents, were recently down 32% to 13.5 cents in premarket trading. Shareholders are generally wiped out in bankruptcy cases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 10, 2024 06:21 ET (10:21 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2474718823","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474718823","pubTimestamp":1728555660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Gritstone bio has filed for chapter 11 bankruptcy, as the clinical-stage biotechnology company continues to explore strategic alternatives.Gritstone on Thursday said it plans to use the bankruptcy court-administered restructuring process to preserve value and bolster its capital position as it continues a Phase 2 study of its immunotherapy candidate in colorectal cancer.The Emeryville, Calif., company, which last month reported encouraging interim data from the study, said the chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware affords it the additional time needed for the data to mature.Gritstone last month also said it had hired Raymond James as its financial adviser to assist in reviewing potential value-maximizing strategies.The company on Thursday said it is in talks with an undisclosed party to act as a lead bidder or restructuring plan sponsor, adding that it plans to present an agreement for a value-maximizing transaction to the bankruptcy court as early","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4568":"美国抗疫概念","GRTS":"Gritstone Oncology Inc."},"translate_title":"Gritstone Bio根据美国破产法第11章申请破产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRTS":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Gritstone bio has filed for chapter 11 bankruptcy, as the clinical-stage biotechnology company continues to explore strategic alternatives. \n\n\n  Gritstone on Thursday said it plans to use the bankruptcy court-administered restructuring process to preserve value and bolster its capital position as it continues a Phase 2 study of its immunotherapy candidate in colorectal cancer. \n\n\n  The Emeryville, Calif., company, which last month reported encouraging interim data from the study, said the chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware affords it the additional time needed for the data to mature. \n\n\n  Gritstone last month also said it had hired Raymond James as its financial adviser to assist in reviewing potential value-maximizing strategies. \n\n\n  The company on Thursday said it is in talks with an undisclosed party to act as a lead bidder or restructuring plan sponsor, adding that it plans to present an agreement for a value-maximizing transaction to the bankruptcy court as early as next week. \n\n\n  Shares of Gritstone, which closed Wednesday at 19.8 cents, were recently down 32% to 13.5 cents in premarket trading. Shareholders are generally wiped out in bankruptcy cases. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 10, 2024 06:21 ET (10:21 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474718823","isCrawlerRequest":true}